ホーム>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>STAT3-IN-1

STAT3-IN-1

カタログ番号GC37688

STAT3-IN-1 (化合物 7d) は、HT29 細胞および MDA-MB 231 細胞でそれぞれ 1.82 μM および 2.14 μM の IC50 値を持つ、優れた選択的かつ経口的に活性な STAT3 阻害剤です。 STAT3-IN-1 (化合物 7d) は腫瘍のアポトーシスを誘導します。

Products are for research use only. Not for human use. We do not sell to patients.

STAT3-IN-1 化学構造

Cas No.: 2059952-75-7

サイズ 価格 在庫数 個数
10 mM * 1 mLin DMSO
$110.00
在庫あり
5mg
$105.00
在庫あり
10mg
$168.00
在庫あり
50mg
$476.00
在庫あり
100mg
$686.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis[1]. IC50: 1.82 μM (STAT3 in HT29 cells), 2.14 μM (STAT3 in MDA-MB 231 cells)[1].

STAT3-IN-1 (compound 7d: 0-10 μM, 48 h) inhibits the STAT3 acetylation at lysine 685 and affected its specific genes expressions[1].STAT3-IN-1 (compound 7d: 0-10 μM, 48 h) induces tumor cells apoptosis in MDA-MB-231 cells[1]. Apoptosis Analysis[1] Cell Line: MDA-MB-231 cell lines.

STAT3-IN-1 (compound 7d: 10, 20 mg/kg, two weeks) arrests tumor growth with low toxicity in mouse-xenograft model[1]. Animal Model: Mouse-xenograft model bearing inoculation of mice breast cancer 4T1 cells[1].

[1]. Li S, et al. Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein. Eur J Med Chem. 2016 Nov 29;124:1006-1018.

レビュー

Review for STAT3-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for STAT3-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.